{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:00:38Z","timestamp":1768438838873,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T00:00:00Z","timestamp":1374451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Egyptian National Cancer Institute"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jnci.2013.05.004","type":"journal-article","created":{"date-parts":[[2013,6,29]],"date-time":"2013-06-29T16:45:28Z","timestamp":1372524328000},"page":"135-142","source":"Crossref","is-referenced-by-count":10,"title":["The prognostic significance of minimal residual disease in adult Egyptian patients with precursor acute lymphoblastic leukemia"],"prefix":"10.1186","volume":"25","author":[{"given":"Mohamed A.","family":"Samra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossam K.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thoraya M.","family":"Abdelhamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahla M.","family":"El Sharkawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser H.","family":"Elnahass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mossaad","family":"Elgammal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaat M","family":"Abdelfattah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salem","family":"Eid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fayek M.","family":"Ghaleb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azza M.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"23","key":"10.1016\/j.jnci.2013.05.004_b0005","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1182\/blood-2012-06-379040","article-title":"Has MRD monitoring superseded other prognostic factors in ALL?","volume":"120","author":"Bruggemann","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jnci.2013.05.004_b0010","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.hoc.2009.07.010","article-title":"Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia","volume":"23","author":"Campana","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"issue":"18","key":"10.1016\/j.jnci.2013.05.004_b0015","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk specific therapy based on molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jnci.2013.05.004_b0020","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jnci.2013.05.004_b0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2141.2003.03988.x","article-title":"Risk factors for adults with Philadelphia chromosome positive acute lymphoblastic leukemia in remission treated with allogeneic bone marrow transplantation: the potential of real time quantitative reverse transcription polymerase chain reaction","volume":"120","author":"Lee","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jnci.2013.05.004_b0030","doi-asserted-by":"crossref","unstructured":"Campana D. Minimal residual disease in acute lymphoblastic leukemia. The education program of American Society of Hematology 2010, 7\u201312.","DOI":"10.1182\/asheducation-2010.1.7"},{"issue":"1","key":"10.1016\/j.jnci.2013.05.004_b0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2141.2011.08795.x","article-title":"Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukemia","volume":"155","author":"Cazzaniga","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jnci.2013.05.004_b0040","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5858\/2003-127-42-FCAOA","article-title":"Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data","volume":"127","author":"Kaleem","year":"2003","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.jnci.2013.05.004_b0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cyto.b.20430","article-title":"Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia; multicentric assessment is feasible","volume":"74","author":"Dworzak","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.jnci.2013.05.004_b0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/asheducation-2002.1.162","author":"Hoelzer","year":"2002","journal-title":"Acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1016\/j.jnci.2013.05.004_b0055","series-title":"Innovative leukemia and lymphoma therapy 2008","first-page":"45","article-title":"Minimal residual disease. I","author":"Van Dongen","year":"2008"},{"key":"10.1016\/j.jnci.2013.05.004_b0060","unstructured":"Norusis M: SPSS 17.0 advanced statistical procedures companion. Upper Saddle-River, N.J. 2009: Prentice Hall, Inc."},{"issue":"6","key":"10.1016\/j.jnci.2013.05.004_b0065","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0889-8588(05)70188-X","article-title":"Treatment of adult ALL according to the protocols of the German Multicenter Study Group for Adult ALL (GMALL)","volume":"14","author":"G\u00f6kbuget","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"issue":"12","key":"10.1016\/j.jnci.2013.05.004_b0070","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jnci.2013.05.004_b0075","unstructured":"Abdel Hamid TM, Mahmoud KH, Kamel AM, El Sharkawy N et al.: Risk adapted chemotherapy treatment for adult acute lymphoblastic leukemia. Egypt J Haematol 2005, 30:579."},{"key":"10.1016\/j.jnci.2013.05.004_b0080","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jnci.2013.05.004_b0085","first-page":"225","article-title":"Gad El Mawla N, Khaled HK, Elzawahry H, Abdelhamid T etal: the impact of intensified induction protocol on remission rate and duration in adult acute lymphoblastic leukemia","volume":"20","author":"Mahmoud","year":"1995","journal-title":"Egypt J Haematol"},{"issue":"5","key":"10.1016\/j.jnci.2013.05.004_b0090","first-page":"1556","article-title":"A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111","volume":"92","author":"Larson","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jnci.2013.05.004_b0095","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Bruggemann","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jnci.2013.05.004_b0100","first-page":"853","author":"Liu","year":"2006","journal-title":"Zhogguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"6","key":"10.1016\/j.jnci.2013.05.004_b0105","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric inspired therapy in adults with Philadelphia chromosome negative acute lymphoblastic leukemia; the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jnci.2013.05.004_b0110","first-page":"S129","article-title":"Risk\/MRD adapted GMALL trials in adult ALL","volume":"83","author":"G\u00f6kbuget","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jnci.2013.05.004_b0115","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1182\/blood.V99.12.4386","article-title":"Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor-B-ALL","volume":"99","author":"Willemse","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jnci.2013.05.004_b0120","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jnci.2013.05.004_b0125","unstructured":"Hoelzer D, G\u00f6kbuget N: Treatment of elderly patients with acute lymphoblastic leukemia. ASCO Education Book 2005, 41st Annual Meeting May 13\u201317:533\u2013539."},{"key":"10.1016\/j.jnci.2013.05.004_b0130","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of Imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"108","author":"Wassmann","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jnci.2013.05.004_b0135","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.leu.2403683","article-title":"Significant reduction of the hybrid BCR\/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia","volume":"19","author":"Pane","year":"2005","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jnci.2013.05.004_b0140","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.2008.07377.x","article-title":"Prospective monitoring of BCR-ABL1 transcripts levels in patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing imatinib combined chemotherapy","volume":"143","author":"Yanada","year":"2008","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.jnci.2013.05.004_b0145","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1182\/blood.V89.7.2602","article-title":"Detection of BCR-ABL transcript in Philadelphia chromosome positive acute lymphoblastic leukemia after marrow transplantation","volume":"89","author":"Raddish","year":"1997","journal-title":"Blood"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1110036213000617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1110036213000617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:01:20Z","timestamp":1715594480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1110036213000617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1110036213000617"],"URL":"https:\/\/doi.org\/10.1016\/j.jnci.2013.05.004","relation":{},"ISSN":["1110-0362"],"issn-type":[{"value":"1110-0362","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}